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Medical and Family History and the Risk of Endometrial Cancer

THESIS ADVISOR (FIRST READER): Prof. Herbert Yu
SECOND READER: Prof. Xiaomei Ma

Abstract
BACKGROUND: Women with a medical history of pelvic inflammatory disease,
endometriosis, polycystic ovary syndrome, diabetes, high blood pressure or other
selected medical conditions, as well as a family history of cancer, are assumed to
be at increased risk of endometrial cancer. This study was designed to test these
assumptions, as evidence for them is lacking. METHODS: We carried out a
population-based case-control study in Connecticut between 2004 and 2008,
including 668 endometrial cancer cases and 674 controls from eligible residents
matched with age. Medical histories and family history of cancers were reported
and conditional logistic regression was used to estimate odds ratio (OR) and
corresponding 95% confidence intervals (95% CI). RESULTS: After adjusting for
various covariates, only the association between a history of high blood pressure
and endometrial cancer risk remained significant (Adjusted OR = 1.71; 95% CI:
1.25-2.34). A family history of cancer in the uterus was directly associated with
endometrial cancer risk (Adjusted OR=2.02; 95% CI: 1.06-3.86).
CONCLUSIONS: A history of high blood pressure and a family history of uterus
cancer among 1st degree relatives are both associated with an increased risk of
endometrial cancer.
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Introduction
Endometrial cancer is the most common type of gynecological cancer in the
United States (US). Endometrial cancer develops in the lining of the uterus, also
called the endometrium. This project aims to investigate the potential role of
medical history and family history of cancer in the etiology of endometrial cancer.
We hypothesize that a medical history of pelvic inflammatory disease,
endometriosis, polycystic ovary syndrome, diabetes or other selected medical
conditions increases the risk of endometrial cancer, and a family history of cancer
is associated with a higher endometrial cancer risk.

Background
Endometrial cancer occurs most often in women from the ages of 55 to 70 years
old and is responsible for 6% of cancer cases in women. The National Cancer
Institute estimates that in 2011, 46,470 American women were diagnosed with
endometrial cancer and 8,120 died from the disease.1 Prolonged exposure to
excessive unopposed estrogens results in continued stimulation of the
endometrium, which is considered a key mechanism in endometrial
carcinogenesis.2 Therefore, factors involving an increased exposure to estrogen
over time may lead to a higher risk of endometrial cancer.

Various studies have shown that hormone replacement therapy (HRT) is
associated with the occurrence of endometrial cancer.3,4 Other conditions that
have been suggested include obesity5, diabetes mellitus6,7, hypertension8,9, and
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metabolic syndrome10. More recently, women with uterine fibroids11 and/or
polysystic ovary syndrome12 were also found to have a higher risk of developing
endometrial cancer, while other gynecological conditions such as endometriosis
and pelvic inflammatory disease did not appear to significantly affect the risk of
endometrial cancer11.

Genetic factors likely play a role in the etiology of endometrial cancer. A family
history of endometrial cancer was identified as a risk factor for endometrial
cancer, although a family history of breast or ovarian cancer had no impact.13
Young women with mutation in the hereditary non-polyposis colorectal cancer
(HNPCC) gene are predicted to have a life-long risk of 50% to develop
endometrial cancer.14

To better understand the etiology of endometrial cancer, we conducted this
research project to systematically evaluate the potential role of medical history
and family history of cancer in a population-based case-control study in
Connecticut.
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Methodology
a. Study Participants
Connecticut residents newly diagnosed with primary endometrial cancer between
October 2004 and September 2008 were recruited to a population-based casecontrol study. Over the study period, study staff from the Rapid Case
Ascertainment (RCA) at the Yale Cancer Center visited 28 Connecticut hospitals
on 1-4 week cycles to obtain medical records and diagnosis reports. Out of 1,663
potentially eligible patients diagnosed at ages 35–80 years, physician consent was
sought for 1,270 patients and obtained from 1,242 (97.8%). Consent for the
remaining 393 patients was not sought because of attainment of planned sample
size. Of the doctor- consented patients, 1,216 were attempted to contact for study
participation and 26 were not contacted due to completion of the study
enrollment. Among the patients for whom contact was attempted, 317 (26.1%)
refused to participate, 19 (1.6%) had died, 13 (1.1%) were too ill to participate, 44
(3.6%) were unable to be located, 68 (5.6%) were unable to be reached through
available telephone numbers, 62 (5.1%) were found to be ineligible due to
ineligible residence (n = 8), mental impairment (n = 7), facility resident (n = 10)
or language barrier (n = 27), and 25 (2.1%) of potential participants had ineligible
diagnoses based on review of their medical records. A total of 668 patients
participated in the study, with a response rate of 59.2% (668 of 1,129) after
excluding 87 ineligible patients.

Controls were matched to cases by age group (35–51, 52–59, 60–64, 65–69, 70–
74 and 75–79 years) and identiﬁed through a pre-letter assisted random-digit
6

dialing (RDD) method. Each selected landline telephone number was ﬁrst
searched in reverse directories to ﬁnd an address for the number, in order to mail a
study letter prior to telephone contact. Potential control subjects were initially
contacted by telephone for determination of study eligibility. Our RDD screen
gathered 8,168 residence numbers, of which 1,995 appeared to have female
residents whose ages were within the desired range of our study. Of these, 1,447
(72.5%) agreed to be further contacted for possible participation in the study.
From the list of potential candidates, we sequentially contacted 1,248 subjects
before the end of the study enrollment, and found 111 subjects ineligible for the
study due to ineligible residence, mental impairment, language barrier, diagnosis
of cancer and ineligible medical conditions, as well as 92 disqualiﬁed for the
study due to illnesses, death, relocation and no response. Of the remaining
subjects, 674 completed in-person interview and 371 refused to participate. The
response rate among the controls was 64.5% (674 of 1,045 subjects).

b. Procedures

Upon the participation agreement, in-home appointments were scheduled for inperson interview and collection of biological specimens. Written informed
consent was obtained at the appointment prior to the start of interview. A
structured questionnaire was used for interview, collecting information on birth
weight, place and date of birth, years of education, self-identiﬁed race and
ethnicity, menstrual and reproductive features during each decade from 20s

7

through 40s, use of oral contraceptives and hormone replacement therapies,
medical history of major chronic illnesses and gynecological disorders, family
history of cancer, smoking and drinking habits, current and lifetime physical
activities, current and lifetime body weight, including weight at age 20s, 30s, 40s,
50s, 60s and 5 years before the interview. Subject’s height and other physical
dimensions were also measured at the time of interview.

c. Statistical Analysis

Our specific variables of interest included medical histories of pelvic
inflammatory disease, endometriosis, polycystic ovary syndrome (PCOS), ovarian
cysts, diabetes, both diabetes and PCOS, wrist fracture/broken after 25 years old,
hip fracture /broken after 25 years old, aspirin regular intake, high blood pressure,
high cholesterol/triglycerides/blood lipids, insulin resistance/metabolic syndrome,
coronary artery disease/heart attack, cirrhosis/hepatitis/other liver problems,
kidney problem/dialysis, growth hormone replacement therapy, ulcerative
colitis/bowel inflammation, mumps , cone or punch biopsy (conization) of cervix/
cryotherapy /freezing therapy of the cervix, and history of breast, uterus, ovary,
colorectal, prostate or lung cancer among 1st degree blood relatives (parents,
siblings, and children). Questionnaire data were first cleaned, merged and
examined using SAS for distributions, outliers and missing values. Univariate
analyses were then performed using the t-tests for continuous variables and χ²
tests for categorical variables. Descriptive statistics on each variable among the
cases and controls were obtained, including means and standard deviations for
8

numerical variables and frequency distributions for categorical or ordinal
variables. Bi-variate logistic regression models were employed to assess the
association between each variable of interest and case/control status by estimating
odds ratios (OR) and their 95% conﬁdence intervals. Multivariate logistic
regression analyses were then performed to adjust for various potential
confounding variables, including age at interview, race (white or other), education
(<12 years, 12 years to 3 years college, college/university, graduate school),
smoking status (current, former, never), body mass index (BMI), age at menarche,
menopausal status (yes/no), age at menopause, parity, estrogen use ( ever/never),
HRT (ever/never), oral contraceptive use (ever/never). These covariates were
chosen based on existing literature and our subject knowledge about the possible
risk factors of endometrial cancer. All tests were two-sided with an alpha value of
0.05. All analyses were conducted with SAS 9.3 (Cary, North Carolina).
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Results
Table 1 shows the demographic and reproductive characteristics of the study
population. Cases and controls were similar with regard to age at interview,
mother’s age at their birth, numbers of siblings, sisters and elder siblings, birth
weight, height and birth place. Controls were more likely to be white (p = 0.033)
and better educated (p <0.001) - 34.2% and 25.6% of control subjects received
college or higher education, respectively, compared to 28.3% and 18.9% of cases,
respectively. Cases had a higher BMI (p < 0.001), higher rates of hypertension (p
< 0.001), diabetes (p < 0.001), and a greater percentage of relatives with
endometrial cancer (p = 0.024). In addition, cases were less likely to be smoker (p
= 0.0187),menopausal hormones (p = 0.006), and they had fewer live births (p <
0.001) and have younger age at first pregnancy (p < 0.001) compared with
controls.

Univariate analyses suggest that patients with PCOS (OR = 4.73; 95% CI: 1.3516.54), diabetes (OR = 1.95; 95% CI: 1.44-2.64), high blood pressure (OR = 2.06;
95% CI: 1.65-2.56), high cholesterol/triglycerides and blood lipids (OR= 1.37;
95% CI: 1.10-1.71) have significantly higher risk of endometrial cancer (Table 2).
However, after adjusting for various covariates, only high blood pressure
remained a statistically significant risk factor (Adjusted OR = 1.71; 95% CI: 1.252.34) (Table 2). Other medical conditions examined included pelvic
inflammatory disease, both diabetes and PCOS, hip fracture/broken hip after 25
years of age, insulin resistance/metabolic syndrome, and growth hormone
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replacement therapy. Since few (< 1%) subjects had reported a history of these
medical conditions, we decided not to show detailed results for these conditions.
No significant associations were found for these conditions, except for pelvic
inflammatory disease (p = 0.001).

After adjusting for various covariates, multivariate analyses of family history of
cancer diagnosis suggests that a diagnosis of cancer in the uterus among 1st degree
blood relatives is significantly associated with an increased risk of endometrial
cancer (Adjusted OR=2.02; 95% CI: 1.06-3.86) (Table 3). A history of other
types of cancers among 1st degree relatives did not appear to influence the risk of
endometrial cancer.
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Discussion

In this population-based case-control study, a medical history of high blood pressure
and a family history of endometrial cancer in the 1st degree relatives were
significantly associated with an increased risk of endometrial cancer. Although there
was also an indication of elevated risk for women with pelvic inflammatory diseases,
the number of subjects reporting such a condition was too few to draw any
conclusion. The association between PCOS and endometrial cancer was first
suggested in 1949 by Speert, who reported an increased incidence of cystic ovaries in
young women with endometrial cancer.15 Jackson and Dockerty in 1957 further
investigated this association by recruiting 43 patients with PCOS. 16 of these women
were identified by examining surgical specimens removed from a group of ‘several
thousand patients’ with endometrial cancer. The remaining 27 patients were women
with symptoms of the PCOS and a confirmatory ovarian biopsy. Endometrial tissue
was available for examination in only 15 of these cases. Thirteen samples showed
‘thickening’, 2 were atrophic, but there were no reported cases of endometrial cancer.
Nevertheless, Jackson and Dockerty concluded that their most important observation
concerned the link between the PCOS and endometrial cancer.16 It has been argued
that this study was not reliable due to methodological problems.17 Many existing
studies which claimed to provide evidence of an increased risk of endometrial cancer
in women with PCOS did not calculate the relative risk.18 Although the study by
Ramzy and Nisker19 included a relative risk estimate in their study which compared
the patients in their study with a cohort of normal women, the numbers were small
and the p value was just reached the level of statistical significance. Another study
12

found an association between PCOS and endometrial cancer, but the relation was
limited only to premenopausal women.17 Overall, the evidence for an increased risk of
endometrial cancer in women with PCOS was inconsistent and inconclusive. The
finding of our study may provide additional evidence to support a possible
association between endometrial cancer and PCOS, but the risk attributable to PCOS
is likely to be small since fewer women with the condition were involved in
endometrial cancer.

Diabetes mellitus has been frequently linked to endometrial cancer. Parazinni has
reported an increased risk of endometrial cancer in diabetic women at age ≥40 years
(OR=3.1; 95% CI: 2.3–4.2), after controlling for age, calendar year at interview,
education, body mass index (BMI) (as categorized variable, <25, 25–30, >30), parity,
oral contraceptive and hormonal replacement therapy use, age at menopause,
hypertension and smoking.20 A population-based prospective cohort study concluded
that diabetes was associated with a 2-fold increased risk, and combination of diabetes
with obesity and low physical activity was associated with a further increased risk for
endometrial cancer. 21 Another case-control study showed a history of diabetes was
significantly related to the risk for endometrial cancer after adjusting for weight and
other reproductive factors, (RR= 2.0; 95% CI: 1.1- 3.6).22 However, our results
indicated that the association between diabetes and the risk of endometrial cancer
became statistically insignificant after multivariate adjustment, which may be
attributable to the relatively small number of women who had diabetes in this study.
The discrepancy in results compared with previous studies could also arise from the
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difference in methodology, covariates being adjusted for, study population, as well as
sample size.

High blood pressure has been reported as a characteristic of endometrial cancer
patients, but the data are less convincing than other risk factors such as overweight,
nulliparity and late manopause. 23 Wynder et al. found a higher proportion of cases
than controls with high blood pressure, 24 but there was a similar excess of patients
with low pressures and the mean pressure did not differ between cases and controls.
Kaplan and Cole stated the relative risk associated with a history of high blood
pressure, after controlling for age and weight, was 1.5,25 but this did not differ
significantly from unity. A history of high blood pressure was identified as a
significant risk factor for endometrial cancer in our study, which confirmed the
association between the two. The putative biologic mechanisms that underlie this
association are unclear at present. It has been speculated that long-term exposure to
high blood pressure may lead to inhibition of apoptosis.14

Our finding regarding family history of uterus cancer is consistent with other studies.
There is some evidence for familial aggregation of endometrial cancer. 26,27 In a
case-control study conducted in northern Italy between 1983 and 1993, a family
history of endometrial cancer was found to increase the risk of the disease.12
However, the proportion of cases attributable to this factor was small in that studyless than 1% of endometrial cancer patients in that population had a family history.
In a large multicentre case-control study conducted by Lucenteforte and Talamini in
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Italy between 1992 and 2006, ORs were 2.1 (95% CI: 0.7-6.4) for those reporting a
family history of endometrial cancer and 1.8 (95% CI: 1.0-3.2) for a family history
of any uterine cancer, indicating a family history of endometrial or any uterine in
first-degree relatives is associated with an increased risk of endometrial cancer. 28

There are several limitations in our study. First, it is possible that the intervieweradministered questionnaires were subject to differential misclassification due to recall
bias. Second, medical history data were self-reported, so misreporting (especially
underreporting) was a possibility. Response rates were modest - 54.9% of cases and
64.5% of controls approached were finally enrolled in the study. Selection bias may
have occurred if the cases and controls who participated were not representative of
the underlying population bases.

Strengths of our study include the population-based study design, the rapid case
ascertainment, and the use of detailed and thorough medical history questionnaires,
measuring 27 different types of medical conditions prior to the diagnosis of
endometrial cancer. Since our study is population-based and included only incident
cases who are confirmed by medical records, survival bias was not a concern, and the
potential for reverse causality was also minimized, if it had not been eliminated
completely.

Endometrial cancer is currently the fourth most common cancer among women. It is
estimated that there will be 47,130 new cases and 8,010 deaths from endometrial
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cancer in the United States in 2012.29 As the incidence/prevalence of high blood
pressure continues to rise in the US and around the world, 30 endometrial cancer
incidence will likely increase. Future studies need to consider how to decrease the
risk of developing endometrial cancer in women with known risk-prone medical
conditions or a family history of endometrial cancer.
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List of Tables
Table 1. Characteristics of the Study Population
Cases
Controls
Number Mean(SD) Number Mean(SD)
668
60.6 (9.5)
665
61.5(10.8)
618
28.6 (6.6)
638
28.3 (6.1)
667
3.9 (2.3)
663
3.7 (2.1)
665
2.4 (1.4)
661
2.3 (1.3)
665
1.4 (1.8)
660
1.3 (1.6)
392
7.1 (1.4)
409
7.0 (1.5)
668 162.7 (6.5)
665 162.5 (6.5)
665 86.5 (23.7)
663 71.5 (16.4)
665
32.7 (8.5)
663
27.1 (6.1)
667
1.8 (1.4)
662
2.1(1.3)
667
23.5(4.7)
662
24.7 (5.0)

Age at interview
Mother's age at birth
Number of siblings
Number of sisters
Number of elder siblings
Birth weight (lb)
Height (cm)
Weight (kg)
BMI
Number of live births
Age at first pregnancy
Birth Place
US
602 (90.3)
Non-US
65 (9.7)
Ethinic group
White
607(90.9)
Other
61(9.1)
Education
<12 yrs
237 (35.5)
12 yrs. to 3 yrs. college
116 (17.4)
College/university
189 (28.3)
Graduate school
126 (18.9)
Smoking Status
Never smoker
364 (54.6)
Former smoker
251 (37.6)
Current smoker
52 (7.8)
Menopausal status
Premenopausal
91 (13.7)
Postmenopausal
575 (86.3)
Oral contraceptive use(ever)
374 (56.3)
Menopausal hormone use(ever) 198 (30.2)
Menarche age
<12 year
186 (28.1)
>=12 year
476 (71.9)
Family history (1st degree
relative with endometrial
cancer)
46 (6.9)
Diagnosis of hypertension (ever) 378 (56.7)
Diagnosis of diabetes (ever)
1.36 (20.4)

p value
0.123
0.444
0.730
0.324
0.817
0.701
0.553
<0.001
<0.001
<0.001
<0.001
0.254

612 (92.0)
53(8.0)
0.033
628 (94.6)
36 (5.4)
<0.001
175 (26.4)
92 (13.9)
227 (34.2)
170 (25.6)
0.0187
311 ( 47.0)
285 (43.1)
66 ( 10.0)
0.031
119 (18.0)
586 (88.5)
440 (66.7)
239 (37.5)

<0.001
0.0056
0.047

153 (23.3)
503 (76.7)

27 (4.1)
257 (38.8)
77 (11.6)

0.024
<0.001
<0.001
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Table 2. Medical History and the Risk of Endometrial Cancer

Case
N (%)
Endometriosis
No
Yes
PCOS
No
Yes
Ovary Cyst
No
Yes
Diabetes
No
Yes
Wrist Fracture/Broken after 25
No
Yes
Aspirin regular intake
No
Yes
High Blood Pressure
No
Yes
High Cholestrol/triglycerides/blood lipids
No
Yes
Coronary Artery Disease/ Heart Attack
No
Yes
Cirrhosis/Hepatitis/Other liver problem
No
Yes
Kidney Problem/ Dialysis needed
No
Yes
Ulcerative Colitis/Bowel inflammation
No
Yes
Mumps
No
Yes
Cone/punch Biopsy of cervix/
Cyrotherapy/Freezing therapy of Cervix
No
Yes

Control
N (%)

p value OR (95% CI)
0.4469

1.19 (0.76-1.87)

Adj* OR (95% CI)
1.29 (0.61-2.73)

620 (93.37) 621 (94.38)
44 (6.63)
37 (5.62)
0.0074 4.73 (1.35-16.54) 5.28 (0.49-57.27)
652 (97.9) 661 (99.55)
14 (2.1)
3 (0.45)
0.8256

0.97 (0.74-1.28)

0.87 (0.58-1.30)

<0.0001 1.95 (1.44-2.64)

1.41 (0.93-2.42)

538 (81.15) 530 (80.67)
125 (18.85) 127 (19.33)
532 (79.64) 588 (88.42)
136 (20.36) 77 (11.58)
0.6316

0.90 (0.58-1.40)

1.40 (0.80-2.47)

0.1205

0.84 (0.67-1.05)

0.76 (0.57-1.03)

<0.0001 2.06 (1.65-2.56)

1.71 (1.25-2.34)

625 (93.98) 617 (93.34)
40 (6.02)
44 (6.66)
423 (63.51) 393 (59.37)
243 (36.49) 269 (40.63)
290 (43.41) 407 (61.2)
378 (56.59) 258 (38.8)
0.0044

1.37 (1.10-1.71)

1.13 (0.84-1.52)

0.1476

1.47 (0.87-2.47)

1.66 (0.87-3.15)

0.1668

0.68 (0.40-1.18)

0.66 (0.29-1.49)

0.9102

1.03 (0.63-1.68)

0.78 (0.39-1.56)

0.7182

0.89 (0.46-1.72)

0.86 (0.38-1.93)

0.2356

0.86 (0.67-1.10)

0.76 (0.53-1.07)

0.1703

1.22 (0.92-1.63)

1.05 (0.70-1.58)

350 (52.79) 399 (60.55)
313 (47.21) 260 (39.45)
627 (94.57) 639 (96.23)
36 (5.43)
25 (3.77)
643 (96.55) 630 (95.02)
23 (3.45)
33 (4.98)
633 (94.9) 632 (95.04)
34 (5.1)
33 (4.96)
649 (97.45) 642 (97.13)
17 (2.55)
19 (2.87)
193 (32.94) 176 (29.73)
393 (67.06) 416 (70.27)

523 (80.83) 541 (83.75)
124 (19.17) 105 (16.25)

*Adjusted for age, race, smoking, menarche age, menopause age, menopause status, parity, BMI, estrogen
usage, oral contraceptives usage, and hormone replacement therapy.
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Table 3. Family History of Cancer and Risk of Endometrial Cancer
Case
N (%)
Breast
No
Yes
Uterus
No
Yes
Ovary
No
Yes
Colorectal
No
Yes
Prostate
No
Yes
Lung
No
Yes

Control
N (%)

P Value
0.396

OR (95% IC)

Adj.*OR (95%CI)

1.13 (0.85-1.51) 0.90 (0.61-1.32)

552 (82.63) 561 (84.36)
116 (17.37) 104 (15.64)
0.0234 1.75 (1.07-2.85) 2.02 (1.06-3.86)
622 (93.11) 638 (95.94)
46 (6.89)
27 (4.06)
0.5944 1.21 (0.59-2.48) 1.01 (0.40-2.60)
651 (97.46) 651 (97.89)
17 (2.54)
14 (2.11)
0.3018 0.83 (0.58-1.19) 0.77 (0.48-1.22)
607 (90.87) 593 (89.17)
61 (9.13) 72 (10.83)
0.1673 1.32 (0.89-1.96) 1.65 (0.96-2.82)
607 (90.87) 618 (92.93)
61 (9.13)
47 (7.07)
0.7792 0.95 (0.69-1.32) 0.85 (0.55-1.30)
587 (87.87) 581 (87.37)
81 (12.13) 84 (12.63)

*Adjusted for age, race, smoking, menarche age, menopause age, menopause status, parity, BMI, estrogen
usage, oral contraceptives usage, and hormone replacement therapy.
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